GeneHealth - Your precision medicine

Paroxysmal Nocturnal Hemoglobinuria

Disease Details

Family Health Simplified

Buy Membership

Description: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening blood disorder characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function.
Type: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematopoietic stem cell disorder. It is not inherited; rather, it results from a somatic mutation in the PIGA gene in hematopoietic stem cells. The disease is characterized by intravascular hemolysis, thrombosis, and bone marrow failure.
Signs And Symptoms: The classic sign of PNH is red discoloration of the urine due to the presence of hemoglobin and hemosiderin from the breakdown of red blood cells. As the urine is more concentrated in the morning, this is when the color is most pronounced. This phenomenon mainly occurs in those who have the primary form of PNH, who will notice this at some point in their disease course. The remainder mainly experience the symptoms of anemia, such as fatigue, shortness of breath, and palpitations.A small proportion of patients report attacks of abdominal pain, difficulty swallowing and pain during swallowing, as well as erectile dysfunction in men; this occurs mainly when the breakdown of red blood cells is rapid, and is attributable to spasm of smooth muscle due to depletion of nitric oxide by red cell breakdown products.Forty percent of people with PNH develop thrombosis at some point in their illness. This is the main cause of severe complications and death in PNH. These may develop in common sites (deep vein thrombosis of the leg and resultant pulmonary embolism when these clots break off and enter the lungs), but in PNH blood clots may also form in more unusual sites: the hepatic vein (causing Budd-Chiari syndrome), the portal vein of the liver (causing portal vein thrombosis), the superior or inferior mesenteric vein (causing mesenteric ischemia) and veins of the skin. Cerebral venous thrombosis, an uncommon form of stroke, is more common in those with PNH.
Prognosis: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease of the blood characterized by the destruction of red blood cells. The prognosis for PNH varies widely among individuals and depends on several factors, including the severity of the disease, the presence of complications such as thrombosis, and the response to treatment.

Historically, the prognosis was poor with a median survival of around 10-15 years from diagnosis, but advances in treatments, particularly with the use of complement inhibitors like eculizumab, have significantly improved outcomes and life expectancy. Regular monitoring and supportive care, including managing symptoms and complications, are critical components in improving prognosis and quality of life for individuals with PNH.
Onset: Paroxysmal nocturnal hemoglobinuria (PNH) often has an insidious onset. Symptoms can develop gradually over time and are highly variable. The condition is characterized by episodes of hemolysis that can occur at any time but are often more noticeable at night or early in the morning.
Prevalence: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, life-threatening disease. The prevalence is estimated to be between 1-1.5 cases per million people worldwide.
Epidemiology: PNH is rare, with an annual rate of 1-2 cases per million. The prognosis without disease-modifying treatment is 10–20 years. Many cases develop in people who have previously been diagnosed with myelodysplastic syndrome. The fact that PNH develops in MDS also explains why there appears to be a higher rate of leukemia in PNH, as MDS can sometimes transform into leukemia or aplastic anemia.25% of female cases of PNH are discovered during pregnancy. This group has a high rate of thrombosis, and the risk of death of both mother and child are significantly increased (20% and 8% respectively).
Intractability: Paroxysmal nocturnal hemoglobinuria (PNH) is considered intractable but manageable. The disease is chronic and requires ongoing treatment to manage symptoms and prevent complications, such as thrombosis and hemolysis. Advances in treatments, such as the use of complement inhibitors like eculizumab, have significantly improved the quality of life and prognosis for patients with PNH, though they do not cure the disease. Regular monitoring and supportive care are essential components of managing PNH.
Disease Severity: Paroxysmal nocturnal hemoglobinuria (PNH) can vary in severity. Some individuals may experience mild symptoms with manageable complications, while others may face more severe issues such as life-threatening blood clots, severe anemia, and frequent infections. Severe cases often require more intensive treatments and monitoring to manage symptoms and prevent complications.
Healthcare Professionals: Disease Ontology ID - DOID:0060284
Pathophysiology: All cells have proteins attached to their membranes, often serving as a mode of communication or signaling between the cell and the surrounding environment. These signaling proteins are physically attached to the cell membrane in various ways, commonly anchored by glycolipids such as glycosyl phosphatidylinositols (GPI). PNH occurs as a result of a defect in the assembling of these glycolipid-protein structures on the surface of blood cells.The most common defective enzyme in PNH is phosphatidylinositol glycan A (PIGA), one of several enzymes needed to make GPI. The gene that codes for PIGA is located on the X chromosome. As males have only a single X chromosome and, in females, one is silenced through X-inactivation), only one active copy of the gene for PIGA is present in each cell regardless of sex. A mutation in the PIGA gene can lead to the absence of GPI anchors expressed on the cell membrane. When this mutation occurs in a hematopoietic stem cell in the bone marrow, all of the cells it produces will also have the defect.Several of the proteins that anchor to GPI on the cell membrane are used to protect the cell from destruction by the complement system, and, without these anchors, the cells are more easily targeted by the complement proteins. Although red blood cells, white blood cells, and platelets are targeted by complement, red blood cells are particularly vulnerable to lysis. The complement system is part of the innate immune system and has a variety of functions, from destroying invading microorganisms by opsonization to direct destabilization by the membrane attack complex. The main proteins that protect blood cells from destruction are decay-accelerating factor (DAF/CD55), which disrupts formation of C3-convertase, and protectin (CD59/MIRL/MAC-IP), which binds the membrane attack complex and prevents C9 from binding to the cell.The symptoms of esophageal spasm, erectile dysfunction, and abdominal pain are attributed to the fact that hemoglobin released during hemolysis binds with circulating nitric oxide, a substance that is needed to relax smooth muscle. This theory is supported by the fact that these symptoms improve on administration of nitrates or sildenafil (Viagra), which improves the effect of nitric oxide on muscle cells. There is a suspicion that chronic hemolysis causing chronically depleted nitric oxide may lead to the development of pulmonary hypertension (increased pressure in the blood vessels supplying the lung), which in turn puts strain on the heart and causes heart failure.Historically, the role of sleep and night in this disease (the "nocturnal" component of the name) has been attributed to acidification of the blood at night due to relative hypoventilation and accumulation of carbon dioxide in the blood during sleep. This hypothesis has been questioned by researchers who note that not all those with PNH have increased hemolysis during sleep, so it is uncertain how important a role sleep actually plays in this disease.
Carrier Status: For paroxysmal nocturnal hemoglobinuria (PNH), there is no carrier status since it is not an inherited disorder. PNH is an acquired hematologic condition caused by somatic mutations in the PIGA gene in hematopoietic stem cells. These mutations lead to the loss of glycosylphosphatidylinositol (GPI) anchors that protect red blood cells from destruction by the complement system.
Mechanism: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematopoietic stem cell disorder characterized by intravascular hemolysis, hemoglobinuria, and a propensity for thrombosis. Below are the details regarding its mechanisms:

**Mechanism:**
The primary mechanism of PNH involves the destruction of red blood cells (RBCs) by the complement system. A defect in the PIG-A gene results in a lack of glycosylphosphatidylinositol (GPI) anchors. Without GPI anchors, several surface proteins, including CD55 (decay-accelerating factor) and CD59 (membrane inhibitor of reactive lysis), which normally protect RBCs from complement-mediated lysis, are absent or deficient. The complement system, particularly the membrane attack complex, then causes hemolysis of these unprotected RBCs, leading to the clinical manifestations of the disease.

**Molecular Mechanisms:**
1. **PIG-A Gene Mutation:** The PIG-A gene, located on the X chromosome, is responsible for the first step in the synthesis of GPI anchors. Somatic mutations in this gene are the primary molecular event in PNH, leading to deficient GPI anchor biosynthesis.

2. **Deficiency of GPI-Anchored Proteins:** Due to the PIG-A mutation, cells lack GPI-anchored proteins such as CD55 and CD59. CD55 normally inhibits the formation of C3 convertase, and CD59 prevents the formation of the membrane attack complex (MAC).

3. **Complement-Mediated Hemolysis:** The absence of CD55 and CD59 makes RBCs highly susceptible to lysis by the complement system. The uncontrolled activation of the complement pathway, especially during the night (when blood pH can drop and trigger complement activation), leads to intravascular hemolysis and subsequent hemoglobinuria.

4. **Thrombosis:** The absence of these protective proteins on other cell types, like platelets and endothelial cells, contributes to a prothrombotic state, which is a significant cause of morbidity and mortality in PNH patients.

In summary, PNH is an acquired stem cell disorder caused by somatic mutations in the PIG-A gene, leading to a deficiency in GPI-anchored proteins that protect RBCs from complement-mediated lysis, resulting in hemolysis and an increased risk of thrombosis.
Treatment: Paroxysmal nocturnal hemoglobinuria (PNH) is treated using targeted therapies that reduce hemolysis and thrombosis. Eculizumab and ravulizumab are the primary monoclonal antibodies used to inhibit complement C5, thereby reducing red blood cell destruction. Supportive treatments include iron and folate supplementation, and sometimes anticoagulants to prevent clotting. Hematopoietic stem cell transplantation may be considered in severe cases. Regular monitoring and a tailored treatment approach are essential for managing the disease effectively.
Compassionate Use Treatment: For paroxysmal nocturnal hemoglobinuria (PNH), compassionate use treatments and off-label or experimental therapies primarily focus on targeting the underlying mechanisms of the disease or managing its symptoms:

1. **Eculizumab (Soliris):** This monoclonal antibody inhibits the terminal complement protein C5. It is FDA-approved for PNH, but access through compassionate use programs may occur in regions where it is not available.

2. **Ravulizumab (Ultomiris):** Similar to eculizumab, this is a longer-acting C5 inhibitor, approved for PNH and may be available through compassionate use in certain cases.

3. **Danicopan (ALXN2040):** This is an experimental oral factor D inhibitor designed to inhibit the alternative pathway of the complement system, currently under clinical trials.

4. **Lactoferrin:** This naturally occurring protein has been studied off-label for its potential to reduce hemolysis and iron overload in PNH patients.

5. **Bone Marrow Transplant:** This remains a curative approach for PNH but is considered in severe cases due to its high risk and complications. It may sometimes be accessed via compassionate use in dire medical situations.

Other investigational treatments in clinical trials may become accessible through experimental programs designed to provide early access to promising therapies still undergoing evaluation.
Lifestyle Recommendations: For individuals with paroxysmal nocturnal hemoglobinuria (PNH), certain lifestyle recommendations can help manage the condition and improve quality of life:

1. **Regular Medical Follow-ups**: Consistent check-ups with a healthcare provider are crucial to monitor the disease and manage symptoms.

2. **Healthy Diet**: A balanced diet rich in vitamins and minerals can support overall health. Avoiding alcohol and foods that can exacerbate symptoms is advised.

3. **Hydration**: Staying well-hydrated helps promote good kidney function and reduce the risk of hemoglobin in the urine.

4. **Monitor for Infections**: Vigilantly monitor for signs of infections, as individuals with PNH are more susceptible. Prompt treatment of infections is essential.

5. **Avoiding Triggers**: Identifying and avoiding activities or situations that can cause undue physical stress or trigger hemolytic episodes is beneficial.

6. **Safe Physical Activity**: Engage in low-impact, moderate exercise to maintain fitness without causing excessive fatigue or stress.

7. **Stress Management**: Techniques such as yoga, meditation, and other relaxation practices can help manage stress levels, which may benefit overall health.

8. **Vaccinations**: Stay up-to-date with vaccinations, particularly those for meningococcal and pneumococcal infections, to reduce the risk of severe infections.

Always consult a healthcare provider before making any significant lifestyle changes or starting new treatments.
Medication: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening blood disorder. Medications used to treat PNH include eculizumab and ravulizumab, which are monoclonal antibodies that inhibit the complement system, helping to prevent red blood cell destruction.
Repurposable Drugs: Repurposable drugs for paroxysmal nocturnal hemoglobinuria (PNH) include:

1. Eculizumab: Originally developed for other types of complement-mediated diseases, it has been successfully repurposed for PNH. It is a monoclonal antibody that inhibits the terminal complement protein C5, reducing hemolysis and thrombotic events.

2. Ravulizumab: A newer complement inhibitor similar to eculizumab, designed for less frequent dosing, also originally targeting complement-mediated conditions.

3. Danazol: A weak synthetic androgen, sometimes used off-label to manage bone marrow failure associated with PNH.

Additionally, supportive treatments like anticoagulants and iron supplements can be part of the management strategy.
Metabolites: Paroxysmal nocturnal hemoglobinuria (PNH) is primarily characterized by the breakdown of red blood cells, leading to the release of hemoglobin into the bloodstream. In terms of metabolites, the most relevant ones include:

1. **Hemoglobin**: Released from lysed red blood cells.
2. **Hemoglobinuria**: Presence of free hemoglobin in the urine, causing dark-colored urine.
3. **Hemosiderin**: Iron-storage complex; iron from lysed red blood cells can accumulate in organs.
4. **Lactate dehydrogenase (LDH)**: Elevated levels due to cell lysis.
5. **Indirect bilirubin**: Increased levels due to the breakdown of hemoglobin.

May I provide further details on this condition?
Nutraceuticals: Nutraceuticals for Paroxysmal Nocturnal Hemoglobinuria (PNH) are not well-documented as specific treatments. PNH is a rare, acquired, life-threatening disease of the blood characterized by the destruction of red blood cells, blood clots, and impaired bone marrow function. The primary treatments focus on managing symptoms and controlling hemolysis, often using medications like eculizumab. Nutraceuticals, such as vitamins and dietary supplements, may benefit overall health but should not replace standard medical treatments. Always consult with healthcare providers before starting any new supplement regimen.
Peptides: In the context of paroxysmal nocturnal hemoglobinuria (PNH), peptides might not be the primary focus of treatment or research, as PNH is a disease that involves the destruction of red blood cells due to a deficiency of certain proteins that protect them from the immune system.

The term "nan" could refer to various aspects depending on the context, but if you're referring to targeted treatments or diagnostic tools, research in nanotechnology might explore innovative ways to deliver treatments or to diagnose conditions at a molecular level. However, specific applications of nanotechnology in PNH treatment are not standard practice yet.

PNH is typically managed through therapies like eculizumab, a monoclonal antibody that inhibits the complement system to prevent hemolysis.